Penbraya also combines elements from Pfizer’s meningococcal vaccines Trumenba and Nimenrix, which together made around $300 million in 2023, and started shipping in the US earlier this year.

In November 2023, GlobalData reported significant changes in the meningococcal vaccine market with the launch of Pfizer's Penbraya. The CDC's Advisory Committee on Immunisation Practices ...

In addition, in October 2023, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for PENBRAYA (meningococcal groups A, B, C, W and Y vaccine) , the first and only pentavalent ...

MenABCWY vaccine (Penbraya): This vaccine protects against serotypes A, B, C, W, and Y. Healthcare professionals may refer to this preparation as a pentavalent vaccine because it helps protect ...

The Meningococcal Vaccine Market Is Experiencing Substantial Growth, driven by Rising Global Incidences of Meningitis and Growing Public Awareness About the Disease's Severity. Valued at Approximately ...

Vaccines protect babies and children from potentially life-threatening diseases. Widespread childhood vaccination has reduced or eliminated deadly diseases like polio and smallpox. Vaccines currently ...

Vaccines are among the best ways a parent can protect their children from certain infectious diseases. Vaccines can also prevent diseases in adults and limit the spread of infection through ...

Staphylococcus Aureus Thwarts Vaccines by Turning on a Protein That Halts Immune Response Dec. 16, 2024 — After dozens of clinical trials, there are still no effective vaccines against ...